TNFSF13: Tumor necrosis factor ligand superfamily member 13
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on TNFSF13, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
- Protein or peptide
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Atacicept | Phase 3 | Vera Therapeutics | Protein or peptide | Inhibitor | Tumor necrosis factor ligand superfamily member 13 inhibitor | 4 | — |
| Sibeprenlimab | Phase 2 | Otsuka Pharmaceutical | Antibody | Inhibitor | Tumor necrosis factor ligand superfamily member 13 inhibitor | 7 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe | Sibeprenlimab | Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 2026-10-22 |
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease | Sibeprenlimab | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-10-06 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) | Sibeprenlimab | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-08-18 |
| Monthly Dosing of Atacicept in IgAN | Atacicept | Phase 2 | Active, not recruiting | Vera Therapeutics, Inc. | 2025-06-13 |
| Atacicept in Multiple Glomerular Diseases | Atacicept | Phase 2 | Recruiting | Vera Therapeutics, Inc. | 2025-05-21 |
| A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | Sibeprenlimab | Phase 2 | Active, not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-15 |
| Phase 2b Open-Label Repeat Kidney Biopsy Study | Sibeprenlimab | Phase 2 | Active, not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-12-18 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Atacicept | Phase 2 | Enrolling by invitation | Vera Therapeutics, Inc. | 2024-11-05 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) | Sibeprenlimab | Phase 3 | Active, not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-02-21 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) | Sibeprenlimab | Phase 2 / Phase 3 | Enrolling by invitation | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-02-21 |
| Atacicept in Subjects With IgA Nephropathy | Atacicept | Phase 3 | Active, not recruiting | Vera Therapeutics, Inc. | 2021-01-20 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Snoring
- 0.41
- Neuroblastoma
- 0.32
- Hypertensive disorder
- 0.29
- Glioblastoma
- 0.29
- Lupus nephritis
- 0.29
- Lymphoma
- 0.26
- Abnormality of the skeletal system
- 0.26
- Familial hyperlipidemia
- 0.21
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713436, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O75888, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets